ATE428429T1 - Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis - Google Patents

Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis

Info

Publication number
ATE428429T1
ATE428429T1 AT01914192T AT01914192T ATE428429T1 AT E428429 T1 ATE428429 T1 AT E428429T1 AT 01914192 T AT01914192 T AT 01914192T AT 01914192 T AT01914192 T AT 01914192T AT E428429 T1 ATE428429 T1 AT E428429T1
Authority
AT
Austria
Prior art keywords
photoretinitis
prostaglandins
treatment
light radiation
eye diseases
Prior art date
Application number
AT01914192T
Other languages
German (de)
English (en)
Inventor
Ryuji Ueno
Yukihiko Mashima
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of ATE428429T1 publication Critical patent/ATE428429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01914192T 2000-03-24 2001-03-23 Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis ATE428429T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19175500P 2000-03-24 2000-03-24
PCT/JP2001/002307 WO2001070233A2 (en) 2000-03-24 2001-03-23 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof

Publications (1)

Publication Number Publication Date
ATE428429T1 true ATE428429T1 (de) 2009-05-15

Family

ID=22706808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914192T ATE428429T1 (de) 2000-03-24 2001-03-23 Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis

Country Status (13)

Country Link
US (1) US7129272B2 (https=)
EP (1) EP1267882B1 (https=)
JP (1) JP2003527430A (https=)
KR (1) KR100788226B1 (https=)
CN (1) CN1443070A (https=)
AR (1) AR030275A1 (https=)
AT (1) ATE428429T1 (https=)
AU (2) AU2001239551B8 (https=)
CA (1) CA2403086C (https=)
DE (1) DE60138371D1 (https=)
NZ (1) NZ521464A (https=)
TW (1) TWI284535B (https=)
WO (1) WO2001070233A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8202909B2 (en) * 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
WO2006106915A1 (ja) * 2005-03-31 2006-10-12 Asahi Glass Company, Limited プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
JPWO2006112313A1 (ja) 2005-04-13 2008-12-11 宇部興産株式会社 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
SG193840A1 (en) * 2008-09-04 2013-10-30 Santen Pharmaceutical Co Ltd HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2a DERIVATIVE AS ACTIVE INGREDIENT
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0761944B2 (ja) * 1989-11-22 1995-07-05 株式会社アールテック・ウエノ 脳機能改善処置剤
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤
JP3964060B2 (ja) * 1997-10-21 2007-08-22 独立行政法人科学技術振興機構 アポトーシス抑制剤
US6087395A (en) 1997-10-21 2000-07-11 Japan Science And Technology Corporation Isocarbacyclin derivatives as apoptosis inhibitors
JP2000169394A (ja) * 1998-12-04 2000-06-20 Yoshitomi Pharmaceut Ind Ltd アポトーシス誘導剤

Also Published As

Publication number Publication date
CA2403086A1 (en) 2001-09-27
CA2403086C (en) 2010-08-17
NZ521464A (en) 2004-09-24
CN1443070A (zh) 2003-09-17
TWI284535B (en) 2007-08-01
WO2001070233A3 (en) 2002-06-13
KR20020081474A (ko) 2002-10-26
JP2003527430A (ja) 2003-09-16
AR030275A1 (es) 2003-08-20
AU2001239551B2 (en) 2005-07-21
US7129272B2 (en) 2006-10-31
EP1267882B1 (en) 2009-04-15
AU3955101A (en) 2001-10-03
EP1267882A2 (en) 2003-01-02
WO2001070233A2 (en) 2001-09-27
AU2001239551B8 (en) 2005-11-24
US20020025985A1 (en) 2002-02-28
KR100788226B1 (ko) 2007-12-26
DE60138371D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
FIU20060389U0 (fi) Luusairauksien hoito
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE428429T1 (de) Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
UY26265A1 (es) Compuestos calciolíticos
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DE60114448D1 (de) Imidazolonderivate zur behandlung viraler krankheiten
EP1359910A4 (en) PROCESS FOR THE TREATMENT OF GLAUCOM II B
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties